Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Alfasigma pens €125M deal for injectable form of HSV treatment
Italian pharma Alfasigma penned a 125 million euro deal for the rights to an injectable form of an HSV encephalitis treatment.
James Waldron
Jan 15, 2026 6:45am
AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF race
Jan 12, 2026 11:00am
Novartis pays SciNeuro $165M for ticket on brain shuttle
Jan 12, 2026 8:49am
Teva lines up $500M in Royalty Pharma funding for vitiligo drug
Jan 12, 2026 7:10am
AirNexis swoops in with $200M series A for COPD asset
Jan 9, 2026 11:01am
Madrigal pays Pfizer $50M for MASH drug with combo potential
Jan 9, 2026 10:50am
